Biomarkers in systemic lupus erythematosus II. Markers of disease activity

Arthritis and Rheumatism

Volumn 50, Issue 7, 2004, Pages 2048-2065

  Illei, Gabor G ^a   Tackey, Edward ^a   Lapteva, Larissa ^a   Lipsky, Peter E ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; DOUBLE STRANDED DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; KYNURENINE; NITRIC OXIDE; SOLUBLE ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; SOLUBLE INTERLEUKIN 2 RECEPTOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; THROMBOMODULIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

B LYMPHOCYTE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; CYTOKINE PRODUCTION; DISEASE ACTIVITY; GENETIC MARKER; GENETIC PREDISPOSITION; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANTIGEN-ANTIBODY COMPLEX; B-LYMPHOCYTES; BIOLOGICAL MARKERS; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 3142729924     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20345     Document Type: Review

References (174)

1. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004;50:1709-20.
2. Spronk PE, Bootsma H, Kallenberg CG. Anti-DNA antibodies as early predictor for disease exacerbations in SLE: guideline for treatment? Clin Rev Allergy Immunol 1998;16:211-8.
3. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus [published erratum appears in Lancet 1995;346: 516]. Lancet 1995;345:1595-9.
4. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus [published erratum appears in Lancet 1995;346: 516]. Lancet 1995;345:1595-9.
5. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE. Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996;23:1891-6.
6. Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis Rheum 1996;39:370-8.
7. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9.
8. Bootsma H, Spronk PE, Ter Borg EJ, Hummel EJ, de Boer G, Limburg PC, et al. The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus: a prospective long-term observation. Ann Rheum Dis 1997;56:661-6.
9. Kallenberg CG, Bootsma H, Spronk PE, Ter Borg EJ, Derksen RH, Kater L. Laboratory tests as predictors of flares in systemic lupus erythematosus: comment on the article by Esdaile et al [letter]. Arthritis Rheum 1997;40:393-4.
10. Swaak AJ, Smeenk RJ. Following the disease course in systemic lupus erythematosus: are serologic variables of any use? J Rheumatol 1996;23:1842-4.
11. Zonana-Nacach A, Sanchez L, Camargo-Coronel A, Martinez-Osuna P, Jimenez-Balderas FJ. Laboratory abnormalities and systemic lupus erythematosus flare: comment on the article by Esdaile et al [letter]. Arthritis Rheum 1997;40:2092-3.
12. Hopkins P, Belmont HM, Buyon J, Philips M, Weissmann G, Abramson SB. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum 1998;31:632-41.
13. Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, et al. Complement activation during systemic lupus erythematosus: C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum 1986;29: 1085-9.
14. Buyon JP, Tamerius J, Belmont HM, Abramson SB. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus: comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum 1992;35:1028-37.
15. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
16. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32:1107-18.
17. Manzi S, Rairie JE, Carpenter AB, Kelly RH, Jagarlapudi SP, Sereika SM, et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum 1996;39:1178-88.
18. Porcel JM, Ordi J, Castro-Salomo A, Vilardell M, Rodrigo MJ, Gene T, et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares. Clin Immunol Immunopathol 1995;74:283-8.
19. Chiu YY, Nisihara RM, Wurzner R, Kirschfink M, Messias-Reason IJ. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients. J Investig Allergol Clin Immunol 1998;8:239-44.
20. Nagy G, Brozik M, Tornoci L, Gergely P. Diagnostic value of combined evaluation of neopterin and anti-DNA antibody levels for assessment of disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:699-705.
21. Mollnes TE, Haga HJ, Brun JG, Nielsen EW, Sjoholm A, Sturfeldt G, et al. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology (Oxford) 1999;38:933-40.
22. Kawano M, Seya T, Koni I, Mabuchi H. Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999;116:542-6.
23. Andersen LS, Petersen J, Svenson M, Bendtzen K. Production of IL-1β, IL-1 receptor antagonist and IL-10 by mononuclear cells from patients with SLE. Autoimmunity 1999;30:235-42.
24. Suzuki H, Takemura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus: enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 1995;38:1055-9.
25. Liou LB. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001;19:515-23.
26. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997;36:1283-9.
27. Chang DM. Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus. Immunol Invest 1997;26: 649-59.
28. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982; 69:1388-92.
29. Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, et al. Th1 (IL-2, interferon-γ [IFN-γ]) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999;115:189-95.
30. Bermas BL, Petri M, Goldman D, Mittleman B, Miller MW, Stocks NI, et al. T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J Clin Immunol 1994;14:169-77.
31. Danieli MG, Paoletti P, Recchioni A, Gabrielli A, Danieli G. Serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and systemic idiopathic vasculitis. Scand J Rheumatol 1993;22:215-9.
32. Airo P, Braga S, Prati E, Brugnoni D, Bettinzioli M, Gorla R, et al. Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol 1992;11:97-100.
33. Tokano Y, Murashima A, Takasaki Y, Hashimoto H, Okumura K, Hirose S. Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Ann Rheum Dis 1989;48:803-9.
34. Manoussakis MN, Papadopoulos GK, Drosos AA, Moutsopoulos HM. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol 1989;50:321-32.
35. Semenzato G, Bambara LM, Biasi D, Frigo A, Vinante F, Zuppini B, et al. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol 1988;8:447-52.
36. Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum 1988;31:729-35.
37. Swaak AJ, Hintzen RQ, Huysen V, van den Brink HG, Smeenk JT. Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course. Clin Rheumatol 1995;14: 293-300.
38. Cuadrado MJ, Marubayashi M, Ortega C, Fernandez-Arcas N, Garcia-Cozar F, Pena J, et al. Relationship of IL-2, IL-2R (CD25+), soluble IL-2R and IL-4 with disease activity in SLE patients. Lupus 1993;2:257-60.
39. Samsonov MY, Tilz GP, Egorova O, Reibnegger G, Balabanova RM, Nassonov EL, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995;4:29-32.
40. Laut J, Senitzer D, Petrucci R, Sablay LB, Barland P, Glicklich D. Soluble interleukin-2 receptor levels in lupus nephritis. Clin Nephrol 1992;38:179-84.
41. Ter Borg EJ, Horst G, Limburg PC, Kallenberg CG. Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990;82:21-6.
42. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, et al, and the European Consensus Study Group for Disease Activity in SLE. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the Eoropean Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
43. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFα, p55 srTNFα, p75srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999;18:17-22.
44. Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases: effect of immunosuppressive therapy. Roum Arch Microbiol Immunol 2001;60: 183-201.
45. Spronk PE, Ter Borg EJ, Huitema MG, Limburg PC, Kallenberg CG. Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1994;53:235-9.
46. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000;9:589-93.
47. Funauchi M, Yu H, Sugiyama M, Ikoma S, Ohno M, Kinoshita K, et al. Increased interleukin-4 production by NK T cells in systemic lupus erythematosus. Clin Immunol 1999;92:197-202.
48. Jones BM, Liu T, Wong RW. Reduced in vitro production of interferon-γ, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-α in systemic lupus erythematosus: weak correlations of cytokine production with disease activity. Autoimmunity 1999;31: 117-24.
49. Barcellini W, Rizzardi GP, Borghi MO, Nicoletti F, Fain C, Del Papa N, et al. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 1996;5:139-45.
50. Amerio P, Frezzolini A, Abeni D, Teofoli P, Girardelli CR, De Pita O, et al. Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity: IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. Clin Exp Rheumatol 2002;20:535-8.
51. Klashman DJ, Martin RA, Martinez-Maza O, Stevens RH. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthritis Rheum 1991;34:276-86.
52. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:565-70.
53. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991;147:117-23.
54. Nishitani Y, Kubo A, Iwano M, Minamino N, Hamano K, Fujimoto T, et al. Imbalance between interleukin-6 and adrenomedullin mRNA levels in peripheral blood mononuclear cells of patients with lupus nephritis. Clin Exp Immunol 2001; 124:330-6.
55. Viallard JF, Taupin JL, Miossec V, Pellegrin JL, Moreau BL. Analysis of interleukin-6, interleukin-10 and leukemia inhibitory factor (LIF) production by peripheral blood cells from patients with systemic lupus erythematosus identifies LIF as a potential marker of disease activity. Eur Cytokine Netw 1999;10:17-24.
56. Hagiwara E, Gourley MF, Lee S, Klinman DK. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-85.
57. Boehme MW, Raeth U, Galle PR, Stremmel W, Scherbaum WA. Serum thrombomodulin-a reliable marker of disease activity in systemic lupus erythematosus (SLE): advantage over established serological parameters to indicate disease activity. Clin Exp Immunol 2000;119:189-95.
58. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995;13: 17-22.
59. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996;5: 571-5.
60. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor a and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
61. Yin Z, Bahtiyar G, Zhang N, Liu L, Zhu P, Robert ME, et al. IL-10 regulates murine lupus. J Immunol 2002;169:2148-55.
62. Llorente L, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Maillot MC, Durand-Gasselin I, et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993;4:421-7.
63. Ferriman EL, Sehmi IK, Jones R, Railton A, Hilton RC, Cuckle HS. False-positive maternal serum screening in systemic lupus erythematosis: a case report [letter]. Prenat Diagn 2000;20:851.
64. Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995;4:393-5.
65. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8.
66. Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001;21:3053-9.
67. Horak P, Scudla V, Hermanovo Z, Pospisil Z, Faltynek L, Budikova M, et al. Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 2001;20:337-44.
68. Tokano Y, Morimoto S, Kaneko H, Amano H, Nozawa K, Takasaki Y, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE): relation to Th1- and Th2-derived cytokines. Clin Exp Immunol 1999;116:169-73.
69. Robak E, Robak T, Wozniacka A, Zak-Prelich M, Sysa-Jedrzejowska A, Stepien H. Proinflammatory interferon-γ-inducing monokines (interleukin-12, interleukin-18, interleukin-15): serum profile in patients with systemic lupus erythematosus. Eur Cytokine Netw 2002;13:364-8.
70. Wong CK, Li EK, Ho CY, Lam CW. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39: 1078-81.
71. Wong CK, Ho CY, Li EK, Tam LS, Lam CW. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. Clin Exp Immunol 2002;130: 345-51.
72. Liu TF, Jones BM. Impaired production of IL-12 in system lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-γ and negatively with disease activity in SLE. Cytokine 1998;10:148-53.
73. Kuroiwa T, Schlimgen R, Illei GG, Boumpas DT. Monocyte response to Th1 stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis. Clin Immunol 2003;106:65-72.
74. Lauwerys BR, Van Snick J, Houssiau FA. Serum IL-12 in systemic lupus erythematosus: absence of p70 heterodimers but presence of p40 monomers correlating with disease activity. Lupus 2002;11:384-7.
75. Min DJ, Cho ML, Cho CS, Min SY, Kim WU, Yang SY, et al. Decreased production of interleukin-12 and interferon-γ is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol 2001;30:159-63.
76. Widner B, Sepp N, Kowald E, Ortner U, Wirleitner B, Fritsch P, et al. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000;201:621-30.
77. Park YB, Kim DS, Lee WK, Suh CH, Lee SK. Elevated serum interleukin-15 levels in systemic lupus erythematosus. Yonsei Med J 1999;40:343-8.
78. Aringer M, Stummvoll GH, Steiner G, Koller M, Steiner CW, Hofler E, et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 2001;40:876-81.
79. Nagahama M, Nomura S, Ozaki Y, Yoshimura C, Kagawa H, Fukuhara S. Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Autoimmunity 2001;33:85-94.
80. Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-8.
81. Tesar V, Jirsa M Jr, Zima T, Kalousova M, Bartunkova J, Stejskalova A, et al. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Med Sci Monit 2002;8:BR24-9.
82. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 1998;7:154-8.
83. Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
84. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002;11: 102-108.
85. Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al, and Members of the British Isles Lupus Assessment Group (BILAG). Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. QJM 1988;69:927-37.
86. Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 1998;37:1334-7.
87. Lard LR, Roep BO, Verburgh CA, Zwinderman AH, Huizinga TW. Elevated IL-16 levels in patients with systemic lupus erythematosus are associated with disease severity but not with genetic susceptibility to lupus. Lupus 2002;11:181-5.
88. Do RK, Chen-Kiang S. Mechanism of BLyS action in B cell immunity. Cytokine Growth Factor Rev 2002;13:19-25.
89. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-9.
90. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 2000;97:3370-5.
91. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-710.
92. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44: 1313-9.
93. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
94. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-71.
95. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001;294:1540-3.
96. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987;70:562-9.
97. Strannegard O, Hermodsson S, Westberg G. Interferon and natural killer cells in systemic lupus erythematosus. Clin Exp Immunol 1982;50:246-52.
98. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-α (IFN-α) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999;115:196-202.
99. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982;25: 401-6.
100. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003;100:2610-5.
101. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
102. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus: the Shwartzman phenomenon revisited. Arthritis Rheum 1994;37:376-83.
103. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg CG. Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE): a long term prospective study. Clin Exp Immunol 1994;97:439-44.
104. Sfikakis PP, Charalambopoulos D, Vayiopoulos G, Oglesby R, Sfikakis P, Tsokos GC. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:5-9.
105. Kling E, Bieg S, Boehme M, Scherbaum WA. Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. Clin Investig 1993;71: 299-304.
106. Tulek N, Aydintug O, Ozoran K, Tutkak H, Duzgun N, Duman M, et al. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with systemic lupus erythematosus. Clin Rheumatol 1996;15:47-50.
107. Ikeda Y, Fujimoto T, Ameno M, Shiiki H, Dohi K. Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus 1998;7:347-54.
108. Mason JC, Kapahi P, Haskard DO. Detection of increased levels of circulating intercellular adhesion molecule 1 in some patients with rheumatoid arthritis but not in patients with systemic lupus erythematosus: lack of correlation with levels of circulating vascular cell adhesion molecule 1. Arthritis Rheum 1993;36: 519-27.
109. Machold KP, Kiener HP, Graninger W, Graninger WB. Soluble intercellular adhesion molecule-1 (sICAM-1) in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1993;68:74-8.
110. Gattorno M, Vignola S, Barbano G, Sormani MP, Sabatini F, Buoncompagni A, et al. Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schonlein purpura and pediatric systemic lupus erythematosus. J Rheumatol 2000; 27:2251-5.
111. Laucella SA, Gaddi E, Balbaryski J, Giraudi V, Cuttica RJ. Soluble intercellular adhesion molecule-1 in paediatric connective tissue diseases. Acta Paediatr 1999;88:399-403.
112. Takasaki Y, Ogaki M, Abe K, Takeuchi K, Ando S, Tokano Y, et al. Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus. J Rheumatol 1998;25:1085-91.
113. Janssen BA, Luqmani RA, Gordon C, Hemingway IH, Bacon PA, Gearing AJ, et al. Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994;33: 1112-6.
114. Sari RA, Taysi S, Erdem F, Yilmaz O, Keles S, Kiziltunc A, et al. Correlation of serum levels of soluble intercellular adhesion molecule-1 with disease activity in systemic lupus erythematosus. Rheumatol Int 2002;21:149-52.
115. Takasaki Y, Abe K, Tokano Y, Hashimoto H. The expression of LFA-1, ICAM-1, CD80 and CD86 molecules in lupus patients: implication for immunotherapy. Intern Med 1999;38:175-7.
116. Tesar V, Masek Z, Rychlik I, Merta M, Bartunkova J, Stejskalova A, et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998;13:1662-7.
117. Egerer K, Feist E, Rohr U, Pruss A, Burmester GR, Dorner T. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus 2000;9:614-21.
118. Ho CY, Wong CK, Li EK, Tam LS, Lam CW. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003;42: 117-22.
119. Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000;43:55-64.
120. Nyberg F, Stephansson E. Elevated soluble E-selectin in cutaneous lupus erythematosus. Adv Exp Med Biol 1999;455:153-9.
121. Boehme MW, Nawroth PP, Kling E, Lin J, Amiral J, Riedesel J, et al. Serum thrombomodulin: a novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994;37:572-7.
122. Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol 2001;28:514-9.
123. Kotajima L, Aotsuka S, Sato T. Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases. Clin Exp Rheumatol 1997;15:59-65.
124. Belmont HM, Levartovsky D, Goel A, Amin A, Giorno R, Rediske J, et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1810-6.
125. Gilkeson G, Cannon C, Oates J, Reilly C, Goldman D, Petri M. Correlation of serum measures of nitric oxide production with lupus disease activity. J Rheumatol 1999;26:318-24.
126. Gonzalez-Crespo MR, Navarro JA, Arenas J, Martin-Mola E, De La Cruz J, Gomez-Reino JJ. Prospective study of serum and urinary nitrate levels in patients with systemic lupus erythematosus. Br J Rheumatol 1998;37:972-7.
127. Oates JC, Christensen EF, Reilly CM, Self SE, Gilkeson GS. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc Assoc Am Physicians 1999;111:611-21.
128. Wanchu A, Khullar M, Deodhar SD, Bambery P, Sud A. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol Int 1998;18:41-43.
129. Zubler RH, Lange G, Lambert PH, Miescher PA. Detection of immune complexes in unheated sera by modified 125I-Clq binding test: effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus. J Immunol 1976;116:232-5.
130. Casali P, Bossus A, Carpentier NA, Lambert PH. Solid-phase enzyme immunoassay or radioimmunoassay for the detection of immune complexes based on their recognition by conglutinin: conglutinin-binding test: a comparative study with 125I-labelled Clq binding and Raji-cell RIA tests. Clin Exp Immunol 1977;29: 342-54.
131. Hay FC, Nineham LJ, Roitt IM. Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase Clq. Clin Exp Immunol 1976;24:396-400.
132. Theofilopoulos AN, Wilson CB, Dixon FJ. The Raji cell radioimmune assay for detecting immune complexes in human sera. J Clin Invest 1976;57:169-82.
133. Harkiss GD, Hazleman BL, Brown DL. A longitudinal study of circulating immune complexes, DNA antibodies and complement in patients with systemic lupus erythematosus: an analysis of their relationship to disease activity. J Clin Lab Immunol 1979;2: 275-83.
134. Abrass CK, Nies KM, Louie JS, Border WA, Glassock RJ. Correlation and predictive accuracy of circulating immune complexes with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1980;23:273-82.
135. Kingsmore SF, Thompson JM, Crockard AD, Todd D, McKirgan J, Patterson C, et al. Measurement of circulating immune complexes containing IgG, IgM, IgA and IgE by flow cytometry: correlation with disease activity in patients with systemic lupus erythematosus. J Clin Lab Immunol 1989;30:45-52.
136. Morimoto C, Sano H, Abe T, Homma M, Steinberg AD. Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes. J Immunol 1982;129:1960-5.
137. Bengtsson A, Nezlin R, Shoenfeld Y, Sturfelt G. DNA levels in circulating immune complexes decrease at severe SLE flares: correlation with complement component Clq. J Autoimmun 1999;13:111-9.
138. Su CC, Shau WY, Wang CR, Chuang CY, Chen CY. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity. Lupus 1997;6:449-54.
139. Viallard JF, Bloch-Michel C, Neau-Cransac M, Taupin JL, Garrigue S, Miossec V, et al. HLA-DR expression on lymphocyte subsets as a marker of disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 2001;125:485-91.
140. Lunardi C, Marguerie C, Bowness P, Walport MJ, So AK. Reduction in T γ δ cell numbers and alteration in subset distribution in systemic lupus erythematosus. Clin Exp Immunol 1991;86:203-6.
141. Robak E, Niewiadomska H, Robak T, Bartkowiak J, Blonski JZ, Wozniacka A, et al. Lymphocyctes Tγδ in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. Mediators Inflamm 2001;10:179-89.
142. Oishi Y, Sumida T, Sakamoto A, Kita Y, Kurasawa K, Nawata Y, et al. Selective reduction and recovery of invariant Vα24JαQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J Rheumatol 2001;28:275-83.
143. Anand A, Dean GS, Quereshi K, Isenberg DA, Lydyard PM. Characterization of CD3+ CD4- CD8- (double negative) T cells in patients with systemic lupus erythematosus: activation markers. Lupus 2002;11:493-500.
144. Bijl M, Horst G, Limburg PC, Kallenberg CG. Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus. Ann Rheum Dis 2001;60:523-6.
145. Inokuma S, Setoguchi K, Ohta T, Matsuzaki Y, Yoshida A. Serum leucine aminopeptidase as an activity indicator in systemic lupus erythematosus: a study of 46 consecutive cases. Rheumatology (Oxford) 1999;38:705-8.
146. Rogers PA, Brenton DP, Hopkinson DA. Changes in the activity and isozyme patterns of glycolytic enzymes during stimulation of normal human lymphocytes with phytohaemagglutinin. Ann Hum Genet 1980;43:213-26.
147. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001;2:764-6.
148. Vernino LA, Pisetsky DS, Lipsky PE. Analysis of the expression of CD5 by human B cells and correlation with functional activity. Cell Immunol 1992;139:185-197.
149. Ebo D, DeClerck LS, Bridts CH, Stevens WJ. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome: relationship with disease activity and treatment. In Vivo 1994;8:577-580.
150. Markeljevic J, Batinic D, Uzarevic B, Bozikov J, Cikes N, Babic-Naglic D, et al. Peripheral blood CD5+ B cell subset in the remission phase of systemic connective tissue diseases. J Rheumatol 1994;21:2225-30.
151. Becker H, Weber C, Storch S, Federlin K. Relationship between CD5+ B lymphocytes and the activity of systemic autoimmunity. Clin Immunol Immunopathol 1990;56:219-25.
152. Huck S, Jamin C, Youinou P, Zouali M. High-density expression of CD95 on B cells and underrepresentation of the B-1 cell subset in human lupus. J Autoimmun 1998;11:449-55.
153. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, et al. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003;48:1332-42.
154. Font J, Pallares L, Martorell J, Martinez E, Gaya A, Vives J, et al. Elevated soluble CD27 levels in serum of patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1996;81:239-43.
155. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum 2002;46: 1417-29.
156. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97:2063-73.
157. Devi BS, van Noordin S, Krausz T, Davies KA. Peripheral blood lymphocytes in SLE: hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells. J Autoimmun 1998;11:471-5.
158. Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 2002;103:54-62.
159. Kato K, Santana-Sahagun E, Rassenti LZ, Weisman MH, Tamura N, Kobayashi S, et al. The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J Clin Invest 1999;104:947-55.
160. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999;42:871-81.
161. Bijl M, Horst G, Limburg PC, Kallenberg CG. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus 2001;10:866-72.
162. Goel N, Ulrich DT, St. Clair EW, Fleming JA, Lynch DH, Seldin MF. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995;38:1738-43.
163. Knipping E, Krammer PH, Onel KB, Lehman TJ, Mysler E, Elkon KB. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:1735-7.
164. Al-Maini MH, Mountz JD, Al-Mohri HA, El-Ageb EM, Al-Riyami BM, Svenson KL, et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus. Lupus 2000;9:132-9.
165. Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, et al. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus? J Autoimmun 1998;11:457-63.
166. Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107:89-95.
167. Rose LM, Latchman DS, Isenberg DA. Elevated soluble fas production in SLE correlates with HLA status not with disease activity. Lupus 1997;6:717-22.
168. Van Lopik T, Bijl M, Hart M, Boeije L, Gesner T, Creasy AA, et al. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse. J Rheumatol 1999;26:60-7.
169. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
170. Kippner L, Klint C, Sturfelt G, Bengtsson AA, Eriksson H, Truedsson L. Increased level of soluble HLA class I antigens in systemic lupus erythematosus: correlation with anti-DNA antibodies and leukopenia. J Autoimmun 2001;16:471-8.
171. Tsuchiya N, Shiota M, Yamaguchi A, Ito K. Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:792-6.
172. Hopper JE, Golbus J, Meyer C, Ferrer GA. Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 2000;20:123-37.
173. Bobkova I, Lysenko L, Polyantseva L, Tareyeva I. Urinary von Willebrand factor as a marker of lupus nephritis progression. Nephron 2001;87:369-70.
174. Molad Y, Miroshnik E, Sulkes J, Pitlik S, Weinberger A, Monselise Y. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clin Exp Rheumatol 2002;20:403-6.